Evidence map›Paper›PMID 34207773›Full record

ReviewCancers2021

An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach.

Natalia Yanguas-Casás, Lucía Pedrosa, Ismael Fernández-Miranda, Margarita Sánchez-Beato

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Mouse models of diffuse large B cell lymphoma.Frontiers in immunology · 2023
    Review
  8. Review
  9. Article
  10. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.Computational and mathematical methods in medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Natalia Yanguas-CasásLymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), C/Joaquín Rodrigo 2, Majadahonda, 28222 Madrid, Spain.ORCID 0000-0003-4368-0176
Lucía PedrosaLymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), C/Joaquín Rodrigo 2, Majadahonda, 28222 Madrid, Spain.
Ismael Fernández-MirandaLymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), C/Joaquín Rodrigo 2, Majadahonda, 28222 Madrid, Spain.
Margarita Sánchez-BeatoLymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), C/Joaquín Rodrigo 2, Majadahonda, 28222 Madrid, Spain.ORCID 0000-0002-0058-7599
Universidad Autónoma de Madrid · ESCentro de Investigación Biomédica en Red de Cáncer · ES

Funding

Dirección General de Universidades e Investigación Consejería de Educación e Investigación de la Comunidad de Madrid B2017/BMD-3778Fundación Científica Asociación Española Contra el Cáncer POSTD18029SANCGILEAD GLD18/00019Instituto de Salud Carlos III CIBERONC CB16/12/00291Instituto de Salud Carlos III DTS17/00039Instituto de Salud Carlos III PI17/00272ISCIII-MINECO AES-FEDER Plan Estatal de I+D+I 2013-2016ISCIII-MINECO AES-FEDER Plan Estatal de I+D+I 2017-2017ISCIII-MINECO AES-FEDER 2017-2020 IFI18/0004
6 · The paper itself

Abstract

Lymphoma research is a paradigm of the integration of basic and clinical research within the fields of diagnosis and therapy. Clinical, phenotypic, and genetic data are currently used to predict which patients could benefit from standard treatment. However, alternative therapies for patients at higher risk from refractoriness or relapse are usually empirically proposed, based on trial and error, without considering the genetic complexity of aggressive B-cell lymphomas. This is primarily due to the intricate mosaic of genetic and epigenetic alterations in lymphomas, which are an obstacle to the prediction of which drug will work for any given patient. Matching a patient's genes to drug sensitivity by directly testing live tissues comprises the "precision medicine" concept. However, in the case of lymphomas, this concept should be expanded beyond genomics, eventually providing better treatment options for patients in need of alternative therapeutic approaches. We provide an overview of the most recent findings in diffuse large B-cell lymphomas genomics, from the classic functional models used to study tumor biology and the response to experimental treatments using cell lines and mouse models, to the most recent approaches with spheroid/organoid models. We also discuss their potential relevance and applicability to daily clinical practice.

Indexed as

B-cell lymphomacancercell linesdiffuse large B-cell lymphomafunctional modelgene editinggenomicsmurine modelsorganoid/spheroidtherapy

Identifiers

PMID34207773
PMCPMC8226720
OpenAlexW3167395641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.